Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 19.02 Billion KRW | -19.5% |
| 2022 | 23.63 Billion KRW | 3.08% |
| 2021 | 22.93 Billion KRW | 46.65% |
| 2020 | 15.63 Billion KRW | -41.42% |
| 2019 | 26.69 Billion KRW | 74.56% |
| 2018 | 15.29 Billion KRW | 43.37% |
| 2017 | 10.66 Billion KRW | -63.22% |
| 2016 | 29 Billion KRW | -40.82% |
| 2015 | 49 Billion KRW | 390.0% |
| 2014 | 10 Billion KRW | -54.55% |
| 2013 | 22 Billion KRW | -45.0% |
| 2012 | 40 Billion KRW | 2757.14% |
| 2011 | 1.4 Billion KRW | -50.0% |
| 2010 | 2.8 Billion KRW | -33.33% |
| 2009 | 4.2 Billion KRW | -25.0% |
| 2008 | 5.6 Billion KRW | -60.19% |
| 2007 | 14.06 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 28.04 Billion KRW | 51.29% |
| 2024 Q1 | 18.53 Billion KRW | -2.59% |
| 2023 Q2 | 11.81 Billion KRW | -49.65% |
| 2023 Q3 | 11.38 Billion KRW | -3.66% |
| 2023 Q4 | 19.02 Billion KRW | 67.14% |
| 2023 FY | 19.02 Billion KRW | -19.5% |
| 2023 Q1 | 23.47 Billion KRW | -0.7% |
| 2022 Q4 | 23.63 Billion KRW | 0.72% |
| 2022 Q3 | 23.46 Billion KRW | -1.66% |
| 2022 Q2 | 23.86 Billion KRW | 1.95% |
| 2022 FY | 23.63 Billion KRW | 3.08% |
| 2022 Q1 | 23.4 Billion KRW | 2.08% |
| 2021 Q2 | 22.47 Billion KRW | 3276.4% |
| 2021 Q3 | 22.34 Billion KRW | -0.59% |
| 2021 FY | 22.93 Billion KRW | 46.65% |
| 2021 Q1 | 665.74 Million KRW | -95.74% |
| 2021 Q4 | 22.93 Billion KRW | 2.62% |
| 2020 Q3 | 15.73 Billion KRW | -2.83% |
| 2020 Q4 | 15.63 Billion KRW | -0.64% |
| 2020 Q2 | 16.19 Billion KRW | -38.8% |
| 2020 FY | 15.63 Billion KRW | -41.42% |
| 2020 Q1 | 26.46 Billion KRW | -0.87% |
| 2019 Q3 | 27.92 Billion KRW | -4.95% |
| 2019 Q1 | 31.46 Billion KRW | 105.74% |
| 2019 FY | 26.69 Billion KRW | 74.56% |
| 2019 Q2 | 29.37 Billion KRW | -6.63% |
| 2019 Q4 | 26.69 Billion KRW | -4.4% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 Q3 | 16.62 Billion KRW | -7.41% |
| 2018 FY | 15.29 Billion KRW | 43.37% |
| 2018 Q4 | 15.29 Billion KRW | -8.0% |
| 2018 Q2 | 17.95 Billion KRW | 0.0% |
| 2017 FY | 10.66 Billion KRW | -63.22% |
| 2017 Q2 | 13.33 Billion KRW | -9.09% |
| 2017 Q4 | 10.66 Billion KRW | -11.11% |
| 2017 Q3 | 11.99 Billion KRW | -10.0% |
| 2017 Q1 | 14.66 Billion KRW | -49.43% |
| 2016 Q1 | 45.5 Billion KRW | -7.14% |
| 2016 Q2 | 27 Billion KRW | -40.66% |
| 2016 Q3 | 26.5 Billion KRW | -1.85% |
| 2016 Q4 | 29 Billion KRW | 9.43% |
| 2016 FY | 29 Billion KRW | -40.82% |
| 2015 Q1 | 20 Billion KRW | 100.0% |
| 2015 Q4 | 49 Billion KRW | 27.27% |
| 2015 Q3 | 38.5 Billion KRW | -1.28% |
| 2015 FY | 49 Billion KRW | 390.0% |
| 2015 Q2 | 39 Billion KRW | 95.0% |
| 2014 Q3 | 8 Billion KRW | 0.0% |
| 2014 Q2 | 8 Billion KRW | -63.64% |
| 2014 FY | 10 Billion KRW | -54.55% |
| 2014 Q4 | 10 Billion KRW | 25.0% |
| 2014 Q1 | 22 Billion KRW | 0.0% |
| 2013 Q4 | 22 Billion KRW | -45.0% |
| 2013 Q2 | 40 Billion KRW | 0.0% |
| 2013 Q1 | 40 Billion KRW | 0.0% |
| 2013 FY | 22 Billion KRW | -45.0% |
| 2013 Q3 | 40 Billion KRW | 0.0% |
| 2012 Q1 | 1.05 Billion KRW | 0.0% |
| 2012 FY | 40 Billion KRW | 2757.14% |
| 2012 Q4 | 40 Billion KRW | 0.0% |
| 2011 FY | 1.4 Billion KRW | -50.0% |
| 2011 Q3 | 1.75 Billion KRW | -16.67% |
| 2011 Q2 | 2.1 Billion KRW | -14.29% |
| 2011 Q1 | 2.45 Billion KRW | -12.5% |
| 2010 Q4 | 2.8 Billion KRW | -11.11% |
| 2010 Q3 | 3.15 Billion KRW | -10.0% |
| 2010 FY | 2.8 Billion KRW | -33.33% |
| 2010 Q1 | 3.85 Billion KRW | -8.33% |
| 2010 Q2 | 3.5 Billion KRW | -9.09% |
| 2009 Q1 | 5.25 Billion KRW | -6.25% |
| 2009 FY | 4.2 Billion KRW | -25.0% |
| 2009 Q4 | 4.2 Billion KRW | -7.69% |
| 2009 Q3 | 4.55 Billion KRW | -7.14% |
| 2009 Q2 | 4.9 Billion KRW | -6.67% |
| 2008 Q1 | 7 Billion KRW | -50.24% |
| 2008 Q2 | 6.3 Billion KRW | -10.0% |
| 2008 Q3 | 5.95 Billion KRW | -5.56% |
| 2008 Q4 | 5.6 Billion KRW | -5.88% |
| 2008 FY | 5.6 Billion KRW | -60.19% |
| 2007 Q1 | 13.03 Billion KRW | 0.0% |
| 2007 FY | 14.06 Billion KRW | 0.0% |
| 2007 Q3 | 16.53 Billion KRW | 9.97% |
| 2007 Q2 | 15.03 Billion KRW | 15.34% |
| 2007 Q4 | 14.06 Billion KRW | -14.95% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -39.499% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 90.583% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 36.313% |
| HANDOK Inc. | 123.78 Billion KRW | 84.628% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -3899.569% |
| Yuhan Corporation | 60.23 Billion KRW | 68.41% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 88.254% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -18587.952% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 76.804% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -3123.338% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -214.507% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -2.728% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -51.203% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -1090.087% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -39.499% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -15798.992% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 84.275% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 40.539% |
| JW Holdings Corporation | 20.65 Billion KRW | 7.889% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -28.347% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 36.574% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 36.574% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -8589.977% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -3176.98% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 61.613% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -327.395% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -39.499% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 79.631% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 36.574% |
| Yuhan Corporation | 60.23 Billion KRW | 68.41% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -81.216% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 52.876% |
| Suheung Co., Ltd. | 74 Billion KRW | 74.289% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 36.574% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -356.667% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -73.57% |
| CKD Bio Corp. | 69.43 Billion KRW | 72.595% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 44.967% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -17.981% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -6096.8% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -8589.977% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 73.614% |
| Boryung Corporation | 151.7 Billion KRW | 87.458% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 75.769% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -214.507% |
| JW Lifescience Corporation | 168 Million KRW | -11225.988% |